Canostix

Manufacturer, Diagnostics, Berlin, Germany

Canostix is developing a blood-based cancer test that combines photonics and pattern recognition, potentially beating liquid biopsy in regard to accuracy, cost and convenience. Starting with the five most common cancers, we create a constantly evolving software solution that upgrades commercially ...

DermoSafe SA

Manufacturer, Diagnostics, Lausanne, Switzerland

Elypta AB

Manufacturer, Diagnostics, Stockholm, Sweden

Elypta is developing the first-ever metabolism-based liquid biopsy platform for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, exceptionally sensitive in studies to date and the low cost assay technology allows for broad use. ...

miRdetect GmbH

Manufacturer, Diagnostics, Bremen, Germany

The number of cancer patients is rapidly increasing worldwide and an early detection of cancer is becoming more and more important. Early detection dramatically increases the probability for higher survival rates and ultimately curing cancer. Furthermore adoption of liquid biopsies for patients ...

oncgnostics GmbH

Manufacturer, Diagnostics, Jena, Germany

Almost half of all men and one third of all women come down with cancer once in their lifetime. But: almost all kinds of cancer are remediable if diagnosed early. In the case of cervical cancer, diagnosed pre-stages are almost 100% curable. oncgnostics GmbH, a spin-off of the university hospital ...

Ourotech

Manufacturer, Diagnostics, Waterloo, Canada

A patient that is diagnosed with cancer today will have a genetic screen on their tumor sample to determine their subtype of cancer. Based on the cancer subtype, they are given a first line of treatment. If that doesn't work, they are given a second line of treatment. If that doesn't work, they ...

SonoView Acoustic Sensing Technologies Ltd liab. Co

Manufacturer, Diagnostics, Nidau, Switzerland

Thrive Earlier Detection Corp.

Manufacturer, Diagnostics, Cambridge, USA

A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated.

UroQuant GmbH

Manufacturer, Diagnostics, Bad Abbach, Germany

Using protein biomarkers, UROQUANT will revolutionise diagnostics. The first product, UROQUANT BC for diagnosing bladder cancer directly from urine will be established as novel gold standard for routine cancer patient care.

Agendia BV

Manufacturer, Diagnostics, Amsterdam, Netherlands

Genomic profiling provides a global ‘map’ of the tumor. Genomic profiling provides insight into the complex molecular characteristics of the cancer. Deeper knowledge of a tumor's gene expression profile is significant, as it can be used to predict the ability of an individual tumor to spread. In ...